Briacell Therapeutics Corp (NASDAQ: BCTX) announced that recruitment and enrolment are open for its advanced breast cancer trial. The company is performing the study in partnership with Incyte. The Phase I/IIa combination study is designed to evaluate BriaCell’s lead candidate, Bria-IMT™, with Incyte’s checkpoint inhibitor, retifanlimab, and IDO1 inhibitor, epacadostat, […]